EGFR and non-small cell lung carcinoma: Consistent with this observation, another observational research study showed rates of documented EGFR testing rate to range between 41 and 97% in patients with newly-diagnosed metastatic NSCLC initiating systemic therapy (including EGFR-TKIs) [20].